Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma

Oncology

Volumn 72, Issue SUPPL. 1, 2007, Pages 104-110

  Yoon, Ki Tae ^a,b   Kim, Ja Kyung ^a,b   Kim, Do Young ^a,b   Ahn, Sang Hoon ^a,b   Lee, Jong Doo ^a   Yun, Mijin ^a   Rha, Sun Young ^a   Chon, Chae Yoon ^a   Han, Kwang Hyub ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Center   (South Korea)

Author keywords

Hepatocellular carcinoma; Positron emission tomography; Tumor staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL RADIOGRAPHY; ADULT; AGED; BONE METASTASIS; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THORAX RADIOGRAPHY; TUMOR VOLUME; ARTICLE; BONE TUMOR; EVALUATION; LIVER TUMOR; LUNG TUMOR; LYMPH NODE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; SCINTISCANNING;

ADULT; AGED; BONE NEOPLASMS; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS;

EID: 37149038485     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111715     Document Type: Conference Paper

References (18)

1. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J: Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-1674.
2. Iglehart JK: The new era of medical imaging - progress and pitfalls. N Engl J Med 2006;354:2822-2828.
3. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S: Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94:3314-3319.
4. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, Collins BT, Di Bisceglie AM: Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792-797.
5. Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, Sakamoto K, Ikari T: Pathology of hepatocellular carcinoma in Japan: 232 consecutive cases autopsied in ten years. Cancer 1983;51:863-877.
6. Yuki K, Hirohashi S, Sakamoto M, Kanai T, Shimosato Y: Growth and spread of hepatocellular carcinoma: a review of 240 consecutive autopsy cases. Cancer 1990;66:2174-2179.
7. Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL: Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000;216:698-703.
8. Honda H, Onitsuka H, Murakami J, Kaneko K, Murayama S, Adachi E, Kanematsu T, Sugimachi K, Masuda K: Characteristic findings of hepatocellular carcinoma: an evaluation with comparative study of US, CT, and MRI. Gastrointest Radiol 1992;17:245-249.
9. 2-weighted and dynamic gadolinium-enhanced MRI versus combined CT during arterial portography and CT hepatic arteriography. J Comput Assist Tomogr 2001;25:777-785.
10. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW: Evaluation of benign vs. malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510-515;discussion 515-516.
11. 18F- fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004;31:1621-1630.
12. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, Hayashi H, Asano T, Ryu M: Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992;33:333-339.
13. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J: In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811-1817.
14. Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, Corstens FH, Oyen WJ: Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002;20:388-395.
15. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ: The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005;104:2658-2670.
16. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM, Ritter JH: Detection of primary hepatic malignancy in liver transplant candidates: Prospective comparison of CT, MR imaging, US, and PET. Radiology 2003;226:533-542.
17. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004;39:961-968.
18. Natsuizaka M, Omura T, Akaike T, Kuwata Y, Yamazaki K, Sato T, Karino Y, Toyota J, Suga T, Asaka M: Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 2005;20:1781-1787.